RecruitingPhase 2Phase 3NCT06694740

Effect of Interferon Gamma as a Treatment for Post-aggressive Immunosuppression in Intensive Care Units, a Randomized Bayesian Double-blind Controlled Trial Versus Placebo

Sponsor

Assistance Publique - Hôpitaux de Paris

Enrollment

170 participants

Start Date

Feb 24, 2026

Study Type

INTERVENTIONAL

Conditions

Post-aggressive Immunosuppression Adult Patients Admitted to Intensive Care With Initial Severity (SOFA of the First 24 Hours Post-admission ≥ 6 Adult Under Mechanical Ventilation, and Presenting an mHLA-DR Less Than 8,000AB/C

Summary

The vast majority of serious clinical situations leading to intensive care (septic shock, polytrauma, acute cerebral aggression, major surgery) are characterized by significant systemic inflammation. Recently, the existence of a common immune response pattern to acute aggression has been demonstrated, and with it the existence of a phenomenon known as post-aggressive immunosuppression (PAIS).

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Interferon Gamma 1-b and a drug called Placebo for people with adult patients admitted to intensive care with initial severity (sofa of the first 24 hours post-admission ≥ 6, adult under mechanical ventilation, and presenting an mhla-dr less than 8,000ab/c, and other related conditions. The study is currently recruiting participants at 2 locations. People eligible for this study include aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGInterferon Gamma 1-b

interferon gamma-1b 2 X 106 IU, injectable solution. Subcutaneous injection every 24 hours for 3 consecutive days (3 total injections)

DRUGPlacebo

Patients randomized to the placebo arm will receive saline injectable solution. Subcutaneous injection every 24 hours for 3 consecutive days (3 total injections)

Locations(2)

Dr de Roquetaillade

Paris, France

Pr Dépret

Paris, France

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06694740